title: [Clinical Analysis of Multiple Myeloma Patients Aged over 80 Years].
abstract: OBJECTIVE
  To explore the clinical features, treatment response and prognosis of multiple myeloma patients aged over 80 years.
  
  
  METHODS
  The clinical data of 23 cases of newly diagnosed multiple myeloma aged over 80 years from February 2007 to July 2014 in our hospital were analyzed retrospectively. The median age was 82, and all the patients had at least 2 complicated diseases. Only 1 patient gave up the chemotherapy because of the poor performance status, the other 22 cases received individualized treatments. Out of 23 patients, 10 received velcade containing regimen (velcade group) chemotherapy, 10 patients received melphalan containing regimen (conventional chemotherapy group) and 2 patients received lenalidomide.
  
  
  RESULTS
  1 patient achieved complete remission, 1 patient achieved very good partial remission, 15 patients achieved partial remission, 1 patient achieved minor remission and 4 patients had progressed. Their median survival time was 19.5 months. Their survival rate of one-year, two-years, three-years were 73.9%, 39.1%, 26.1%, respectively. The median OS time and PFS time were 21.5 (9-46) vs 13 (3-23) months (P = 0.405) and 16 (5-38) vs 10 (3-19) months in the velcade group and conventional chemotherapy group, respectively. 9 cases had been alive until December 2015, while 14 cases had died.
  
  
  CONCLUSIONS
  Multiple meloma patients aged over 80 years diagnosed at advanced stage often accompanied with previous underlined diseases. Treatment should be individualized based on the evaluation of patient status. The OS and PFS time of patients could be prolonged using the velcade containing chemotherapy.
authors.affiliation: Department of Hematology and Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
authors.forename: Man
authors.initials: M
authors.lastname: Shen
authors.affiliation: Institute of Basic Medical Sciences, Academy of Military Medical Sciences. Beijing 100850, China.
authors.forename: Xiao-Xia
authors.initials: XX
authors.lastname: Jiang
authors.affiliation: Department of Hematology and Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
authors.forename: Na
authors.initials: N
authors.lastname: An
authors.affiliation: Department of Hematology and Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
authors.forename: Jia-Jia
authors.initials: JJ
authors.lastname: Zhang
authors.affiliation: Department of Hematology and Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China.
authors.forename: Zhong-Xia
authors.initials: ZX
authors.lastname: Huang
authors.affiliation: Department of Hematology and Oncology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100043, China. E-mail: lixin0628@sohu.com.
authors.forename: Xin
authors.initials: X
authors.lastname: Li
mesh_terms: D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069286:Bortezomib / Q000627:therapeutic use; D006801:Humans; D000077269:Lenalidomide; D008558:Melphalan / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000628:therapy*; D011379:Prognosis; D012074:Remission Induction; D012189:Retrospective Studies; D015996:Survival Rate; D013792:Thalidomide / Q000031:analogs & derivatives / Q000627:therapeutic use
chemical_list: D013792:Thalidomide; D000069286:Bortezomib; D000077269:Lenalidomide; D008558:Melphalan